Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Synthesis and clinical application of new drugs approved by FDA in 2023
Yatao Wang, Pengcheng Yang, Yanfeng Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116124-116124
Closed Access | Times Cited: 15
Insights into the Adsorption Properties of Mixed Matrix Membranes (Pebax 1657-g-Chitosan-PVDF-Bovine Serum Albumin@ZIF-CO3-1) for the Antiviral COVID-19 Treatment Drugs Remdesivir and Nirmatrelvir: An In Silico Study
Iman Salahshoori, Narjes Montazeri, Amirhosein Yazdanbakhsh, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 26, pp. 31185-31205
Closed Access | Times Cited: 33
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 9
Adverse events related to drug–drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review
Valeria Conti, Nicola Bertini, Rosaria Ricciardi, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 275-292
Closed Access | Times Cited: 7
Point-of-Care Devices for Viral Detection: COVID-19 Pandemic and Beyond
Sumit Kumar Yadav, Damini Verma, Ujala Yadav, et al.
Micromachines (2023) Vol. 14, Iss. 9, pp. 1744-1744
Open Access | Times Cited: 17
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications
Zhen-Xi Niu, Jing Hu, Jinfeng Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116446-116446
Closed Access | Times Cited: 6
The Discovery of inhibitors of the SARS-CoV-2 S protein through computational drug repurposing
Ana Isabel Avilés‐Alía, João Zulaica, Juan J. Pérez, et al.
Computers in Biology and Medicine (2024) Vol. 171, pp. 108163-108163
Open Access | Times Cited: 5
Structure–Activity Relationship of Ciprofloxacin towards S-Spike Protein of SARS-CoV-2: Synthesis and In-Silico Evaluation
Sahil Kumar, Papiya Dey, Arup Kumar Pathak, et al.
Journal of Chemical Information and Modeling (2025)
Closed Access
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience
Andrea Duminuco, Anna Bulla, Rosamaria Rosso, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 111-111
Open Access
The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health
A. Siddiqui, Imshaal Musharaf, Bashar Haruna Gulumbe
Therapeutic Advances in Infectious Disease (2025) Vol. 12
Open Access
A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions
Zhiqing Fu, Yan Guo, Shuai Li, et al.
Cardiology Discovery (2025)
Open Access
Host-targeted antivirals against SARS-CoV-2 in clinical development - prospect or disappointment?
André Schreiber, Stephan Ludwig
Antiviral Research (2025) Vol. 235, pp. 106101-106101
Open Access
Development with greenness evaluation and validation of stability indicating ion-pair reverse phase HPLC method for determination of related substances and assay of Nirmatrelvir drug substance
Sonali Mehendale-Munj, Manoj A. Mangukiya, Aman A. Desai, et al.
Analytical Chemistry Letters (2025) Vol. 15, Iss. 1, pp. 65-82
Closed Access
Involvement of virus infections and antiviral agents in schizophrenia
Alejandro Borrego-Ruiz, Juan J. Borrego
Psychological Medicine (2025) Vol. 55
Closed Access
In silico studies to understand the interactions of flavonoid inhibitor with nsp12-RNA dependent RNA polymerase of SARS-CoV-2 and its homologs
Shamiya Anwar Kizhakkiniyakath, Tejaswini Choudhury, Madhan Vishal Rajan, et al.
Biochemistry and Biophysics Reports (2025) Vol. 42, pp. 101975-101975
Closed Access
Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024
Maja Vukovikj, Angeliki Melidou, Priyanka Nannapaneni, et al.
Eurosurveillance (2025) Vol. 30, Iss. 10
Open Access
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
Bahman Amani, Arash Akbarzadeh, Behnam Amani, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Open Access | Times Cited: 14
Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses
Chiranjib Chakraborty, Manojit Bhattacharya, Abdulrahman Alshammari, et al.
Journal of Infection and Public Health (2023) Vol. 16, Iss. 12, pp. 1961-1970
Open Access | Times Cited: 12
Antivirals for Broader Coverage against Human Coronaviruses
Mia Outteridge, Christine M. Nunn, Kevin M. Devine, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 156-156
Open Access | Times Cited: 4
Analyzing the expression pattern of the noncoding RNAs (HOTAIR, PVT‐1, XIST, H19, and miRNA‐34a) in PBMC samples of patients with COVID‐19, according to the disease severity in Iran during 2022–2023: A cross‐sectional study
Khadijeh Khanaliha, Javid Sadri Nahand, Alireza Khatami, et al.
Health Science Reports (2024) Vol. 7, Iss. 2
Open Access | Times Cited: 4
Influence of Solvent Selection on the Crystallizability and Polymorphic Selectivity Associated with the Formation of the “Disappeared” Form I Polymorph of Ritonavir
Chang Wang, Cai Y., Richard S. Hong, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 7, pp. 3525-3539
Open Access | Times Cited: 3
An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 9
COVID-19: An Update on the Latest Therapeutic Agents
Ke-Yan Loo, Loh Teng‐Hern Tan, Jodi Woan‐Fei Law, et al.
Progress In Microbes & Molecular Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top